Rohan Moghe, Alex J Mathew, David Choi, David T Rubin
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis which can present as an extraintestinal manifestation of ulcerative colitis (UC). There is significant overlap in the pathophysiology of both diseases, including interleukin (IL)-23 overexpression. Guselkumab, a selective IL-23 inhibitor, has been shown to be an effective treatment option in UC and has successfully treated PG in case reports. However, there is limited literature on concomitantly treating PG and UC. We present a case in which guselkumab contributed to the treatment of PG in a patient with UC, while also maintaining clinical remission of UC.